Company intelligence / Profile preview

Scotia Pharmaceuticals Limited

United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Scotia Pharmaceuticals was a UK-based biotechnology/pharmaceutical company focused on the development of small molecule and fatty acid derivative therapeutics for metabolic and oncology indications. Its main drug candidates included SOC‑0150 for diabetic neuropathies, lithium gamolenate targeting prostaglandin synthases for pancreatic cancer, Glamepa for neoplasms, and Meglumine‑GLA for bladder cancer. All known programs were discontinued prior to approval or commercialization. The company was dissolved in July 2019.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculesFatty acid derivativesOther small molecule therapeutics
Industry: Biotech

Beyond the preview

Go deeper on Scotia Pharmaceuticals Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scotia Pharmaceuticals Limited.